Invalidity dossier
US 9611316
Human cytomegalovirus neutralising antibodies and use thereof
Current assignee: Humabs LLC
Added 9/21/2026, 9:26:20 AM
Active provider: DeepSeek · deepseek-flash
Patent summary
Title, assignee, inventors, filing/issue dates, abstract, and a plain-language overview of the claims.
Patent Overview: US9611316B2
Title: Human cytomegalovirus neutralising antibodies and use thereof
Patent number: US9611316B2 | Application: US14/938,438 | Publication: US20160289302A1
Inventors: Antonio Lanzavecchia, Annalisa Macagno
Current assignee (as listed): Humabs LLC. Original assignee: Institute for Research in Biomedicine (IRB). The source notes listed assignees may be inaccurate and that Google has not analyzed or warranted the assignment list.
Key dates (as listed): Priority date 2007-01-04 (GB0700133.2); filing date 2015-11-11; granted 2017-04-04. Legal status listed as "Expired – Fee Related," with anticipated expiration 2028-01-03. The source states legal status is an assumption, not a legal conclusion.
Purpose: The invention "relates to potent, neutralizing antibodies having specificity for human cytomegalovirus [hCMV], and immortalized B cells that produce such monoclonal antibodies," plus the epitopes they bind and uses in screening, diagnosis, prophylaxis, and therapy.
Plain-language scope (per the excerpt):
- Claims a neutralizing antibody/antibody fragment specific for a combination of hCMV proteins UL130 and UL131A, or UL128, UL130 and UL131A (as described in the summary-of-invention text).
- Nucleic acids encoding such antibodies; vectors; cells; immortalized B cell clones; epitopes; immunogenic polypeptides; binding ligands; pharmaceutical compositions; and diagnostic kits.
- Methods of producing/screening such antibodies, preparing recombinant cells by sequencing antibody nucleic acid from immortalized B cells, and screening polypeptide libraries for immunogenic candidates.
- Figures describe antibodies 1F11, 2F4, 5A2, 9A11 and sequences (SEQ ID NOs: 1–10, 17–20).
What the excerpt does not establish: It provides no complete claims, no full specification or sequence listings, no experimental data beyond figure captions, and no assessment of validity, enforceability, inventorship, prior art, or actual ownership. The excerpt appears truncated and contains an apparent typo ("UL and UL131A"). No clinical or commercial status is shown.
Source: https://patents.google.com/patent/[US9611316](/patent/US9611316)/en
Generated 10/1/2026, 10:02:24 PM
Cases on file (0)
Specific litigation cases in our database that name US patent 9611316. The free-form analysis below may also discuss cases beyond this list.
No cases on file mention this patent. Upload a CSV or add a case manually in Admin → Manage litigation cases.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Proceedings on file (0)
All PTAB activity →AIA trial proceedings (IPR / PGR / CBM) filed at the USPTO Patent Trial and Appeal Board against this patent. Sourced from the USPTO Open Data Portal and refreshed every six hours; each proceeding number deep-links to the PTAB E2E docket.
No PTAB proceedings on file. This patent has not been challenged via IPR, PGR, or CBM. The absence is itself a signal — well-asserted patents eventually attract IPRs. The LLM analysis below may surface filings the ODP feed hasn’t indexed yet.
PTAB challenges
AIA trial proceedings at the USPTO Patent Trial and Appeal Board — IPR, PGR, and CBM. Petitioners, judge panels, claim-level invalidation outcomes from Final Written Decisions, and Federal Circuit appeals. The single most important defensive datapoint after litigation history.
Assignment history
Inventors, original assignee, and the chain of ownership recorded with the USPTO — including the correspondent attorney who recorded each assignment, since shell-LLC chains often share one repeat-player attorney even when the entity names look unrelated. Surfaces NPE / patent-troll patterns: shell-entity transfers, known asserters in the chain, repeat correspondent fingerprints, pre-litigation assignments, and bankruptcy fire-sales.
Prior art
Earlier patents, publications, and products that may anticipate or render the claims unpatentable.
Obviousness
Combinations of prior art that suggest the claimed invention would have been obvious under 35 U.S.C. § 103.
Extensions
Patent term adjustments, term extensions, continuations, divisionals, family members, and expiration dates.
Derivative works
Defensive disclosure: derivative variations of each claim designed to render future incremental improvements obvious or non-novel.